Pipeline

Sonnet Pipeline

Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates, with a lead compound, SON-080, ready to enter Phase 2 development.

Program Indications Discovery Preclinical Phase 1 Phase 2
SON-080 (low-dose IL-6) Chemotherapy Induced Peripheral Neuropathy
Discovery Phase complete
Pre-clinical Phase complete
Phase I Phase in progress
Phase II Phase not started
FHAB Platform
SON-1010 (IL12-FHAB) Undisclosed Solid Tumor
Discovery Phase complete
Pre-clinical Phase in progress
Phase I Phase not started
Phase II Phase not started
SON-1210 (IL15-FHAB-IL12) Undisclosed Solid Tumor
Discovery Phase complete
Pre-clinical Phase in progress
Phase I Phase not started
Phase II Phase not started
SON-2014 (GMcSF-FHAB-IL18) Early Stage Cancer
Discovery Phase in progress
Pre-clinical Phase not started
Phase I Phase not started
Phase II Phase not started
SON-3015 (Anti-IL6-FHAB-Anti-TGFβ) Tumor and Bone Metastases
Discovery Phase in progress
Pre-clinical Phase not started
Phase I Phase not started
Phase II Phase not started